New Delhi, Nov 14 (PTI) Drug firm Cadila Healthcare todayreported a 32.48 per cent rise in its consolidated net profitto Rs 503.3 crore for the second quarter ended September 30,mainly on account of robust sales in the US and India.
The company had posted a net profit of Rs 379.9 crore forthe corresponding period of the previous fiscal, CadilaHealthcare said in a BSE filing.
Consolidated total revenue from operations also rose toRs 3,234 crore for the quarter under consideration as againstRs 2,403.5 crore in the same period a year ago.
The company's sales in the US rose by 66 per cent to Rs1,644 crore for the quarter ended September 30, CadilaHealthcare said.
The Indian formulations business also grew by 15 percent, excluding the excise duty, to Rs 895 crore, it added.
"During the quarter, the company launched four newproducts in the US, including Mesalamine delayed release 1.2 gtablets (generic version of Lialda) with a 180 daysexclusivity," Cadila Healthcare said.
Shares of Cadila Healthcare were today closed at Rs448.50 per scrip on BSE, down 0.50 per cent from its previousclose. PTI AKTBAL.
This is unedited, unformatted feed from the Press Trust of India wire.